SOLVE FSHD AnnouncesNew Collaborative Research Grants to Accelerate Novel Potential Therapeutics for Facioscapulohumeral Muscular Dystrophy (FSHD) VANCOUVER, B.C., July 11, 2023 – SOLVE FSHD, a venture philanthropy organization catalyzing innovation and removing barriers to accelerate new therapies for FSHD, announced today that it has awarded grants totalling USD $1.4M to four new collaborative research projects that address critical …
SOLVE FSHD invests in Epic Bio for the development of a novel treatment for Facioscapulohumeral Muscular Dystrophy Investment will further accelerate the development of EPI-321 VANCOUVER, B.C., April 18, 2023 – SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to accelerate a cure for FSHD, announced today an investment in Epic Bio, a biotechnology …
Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers – Fundraising led by Cambrian BioPharma and Solve FSHD –– Company expands pipeline with new program, VTA-120, for the treatment of facioscapulohumeral muscular dystrophy (FSHD) – Baltimore, MD, October 12, 2022 – Vita Therapeutics, a cell engineering company harnessing …
SOLVE FSHD Provides Funding to n-Lorem for a Collaboration to Expand Understanding of FSHD2, a Rare Form of Muscular Dystrophy SOLVE FSHD contributes more than $1 million to n-Lorem to support research efforts to inform a therapeutic strategy for FSHD2 nano-rare patients SAN DIEGO, Calif., Sept. 9, 2022, n-Lorem, a nonprofit foundation, today announced that Solve …
VANCOUVER, B.C. – Following SOLVE FSHD’s recent acclaimed launch, the organization is pleased to formally announce the appointment of Dr. Eva Chin as the Executive Director. SOLVE FSHD’s Founder, Chip Wilson, has personally committed USD100 million to find a cure for facioscapulohumeral muscular dystrophy (FSHD), a rare disease he was diagnosed with at the age …
VANCOUVER, B.C. – SOLVE FSHD, the venture-philanthropy organization founded by entrepreneur Chip Wilson, announces its financial support to the FSHD Canada Foundation’s strategic investment of US$1.2M in biomarker grant funding to facilitate biomarker research in facioscapulohumeral muscular dystrophy (FSHD). The FSHD Canada Foundation acknowledges the generous support of SOLVE FSHD towards funding these grants. The …